2342 Stock Overview
Develops, distributes, and licenses genetically modified animals and antibodies in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Transgenic Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥178.00 |
| 52 Week High | JP¥294.00 |
| 52 Week Low | JP¥176.00 |
| Beta | 0.66 |
| 1 Month Change | -12.32% |
| 3 Month Change | -25.83% |
| 1 Year Change | -32.83% |
| 3 Year Change | -59.82% |
| 5 Year Change | -56.16% |
| Change since IPO | -91.76% |
Recent News & Updates
Shareholder Returns
| 2342 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -6.3% | -1.7% | -1.5% |
| 1Y | -32.8% | 18.5% | 13.7% |
Return vs Industry: 2342 underperformed the JP Biotechs industry which returned 18.5% over the past year.
Return vs Market: 2342 underperformed the JP Market which returned 13.7% over the past year.
Price Volatility
| 2342 volatility | |
|---|---|
| 2342 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 2342 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 2342's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 236 | Kenji Fukunaga | transgenic-group.co.jp |
Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of clinical trial reports; as well as hospital support services.
Transgenic Group Inc. Fundamentals Summary
| 2342 fundamental statistics | |
|---|---|
| Market cap | JP¥2.96b |
| Earnings (TTM) | -JP¥226.00m |
| Revenue (TTM) | JP¥13.02b |
0.2x
P/S Ratio-13.1x
P/E RatioIs 2342 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2342 income statement (TTM) | |
|---|---|
| Revenue | JP¥13.02b |
| Cost of Revenue | JP¥10.82b |
| Gross Profit | JP¥2.20b |
| Other Expenses | JP¥2.42b |
| Earnings | -JP¥226.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -13.57 |
| Gross Margin | 16.88% |
| Net Profit Margin | -1.74% |
| Debt/Equity Ratio | 46.5% |
How did 2342 perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield-22%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 19:08 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Transgenic Group Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pravin Gondhale | Virtua Research Inc. |